Salute e Benessere

SM addresses rising consumer demand for beauty and wellness

"Beauty and wellness have shown significant growth across every demographic," said SM Retail President Jonathan Ng. "At SM, we will continue to be at the forefront of meeting customers' evolving preferences by offering enriching experiences through suitable and unique products and services." "Beauty and wellness have shown significant growth across every demographic," said SM Retail PresidentJonathan Ng. "At SM, we will continue to be at the forefront of…
PR Newswire
24/09/2025

Xeltis poised for commercialization following excellent clinical data from aXess…

The results from the trial showed that aXess delivered major improvements on all key clinical metrics compared to the standard of care. aXess demonstrated superior sustained patency across both primary and secondary outcomes*, compared to other arteriovenous grafts (AVG), while requiring fewer interventions, also showing a lower re-intervention rate and high infection resistance compared to fistulas. Many of the patients in the trial had a history of failed AVG's or fistulas for dialysis or had…
PR Newswire
24/09/2025

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two…
PR Newswire
24/09/2025

NHS Access to Medical Cannabis Could Unlock £13.3bn and Return Thousands to Work

Since its legalisation in 2018, private prescriptions have already contributed around £283 million in Gross Value Added (GVA) by helping people get well and back to work. Since its legalisation in 2018, private prescriptions have already contributed around £283 million in Gross Value Added (GVA) by helping people get well and back to work. Roughly 2.8 million people in the UK are currently locked out of employment due to long-term illness. Polling conducted alongside the Cebr study, found...
PR Newswire
24/09/2025

CARBIOS presents its 2025 half-year results and confirms its objective to build…

CARBIOS has reduced its operating expenses and has a strong cash position of€72 million as of June 30, 2025, providing a cash horizon of more than 12 monthsThe Longlaville plant construction project is now supported by:Major progress with public financers ADEME and the Regional CouncilClear interest from private investors, conditional upon the pre-sale of a significant portion of the future plant’s capacity, which has not yet been achievedRecent regulatory developments that...
Nasdaq GlobeNewswire
24/09/2025

New Novartis data further support benefits of Kesimpta® in relapsing MS…

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS)following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies 1 Following switch to Kesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse rates (ARR) were observed 1 In the separate ALITHIOS open-label extension study,...
Nasdaq GlobeNewswire
24/09/2025

Roche presents new data for OCREVUS and fenebrutinib across broad patient…

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infants potentially exposed to OCREVUS during pregnancy or breastfeeding exhibit antibody responsesFenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeksBasel, 24 September 2025 - Roche (SIX: RO,...
Nasdaq GlobeNewswire
24/09/2025

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA…

"FDA has now provided its feedback on the final module of our PMA submission for U.S. market approval to sell RefluxStop® in the U.S. The feedback is positive and can be addressed efficiently in our view. We are meeting with FDA on October 3rd to discuss the best path forward in addressing a few outstanding questions and requests. Depending on the outcome of this meeting, we expect to provide our responses to FDA's feedback within a timeframe ranging from a few weeks to a few months. We are…
PR Newswire
24/09/2025

Correction of a Material Error Relating to the Total Number of Voting Rights and…

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE) corrects the information relating to the total number of shares and voting rights comprising its share capital. As part of the preparation for the General Meeting on September 30, 2025, OSE identified a...
Nasdaq GlobeNewswire
24/09/2025

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from…

The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety profileSYT-510 demonstrated penetration in the central nervous system and a pharmacodynamic effect on the brain BASEL, Switzerland, Sept.24, 2025(GLOBE NEWSWIRE) -- Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its lead asset, SYT-510, a...
Nasdaq GlobeNewswire
24/09/2025

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to…

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovationThe fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategySanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companiesParis, September 24, 2025...
Nasdaq GlobeNewswire
24/09/2025

Press release: Availability of the Q3 2025 Aide mémoire

Availability of the Q3 2025 Aide mémoireParis, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second...
Nasdaq GlobeNewswire
24/09/2025

BMC Medical Showcases Innovations in Sleep and Respiratory Care at ERS 2025 in…

Alongside the exhibition, BMC will host a sponsored workshop session:"The Future of CPAP Monitoring: What Needs to Change Today?"Tuesday, September 15, 14:00–14:45 | Room E103–104 Alongside the exhibition, BMC will host a sponsored workshop session: "The Future of CPAP Monitoring: What Needs to Change Today?"Tuesday, September 15, 14:00–14:45 | Room E103–104 The session will feature leading experts including: The discussion will explore the transition from a one-size-fits-all…
PR Newswire
24/09/2025

SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging…

Key Takeaways from the SGLT2 Inhibitors Market Report Key Takeaways from the SGLT2 Inhibitors Market Report Discover which indication is expected to grab the major SGLT2 inhibitors market share @SGLT2 Inhibitors Market Report Key Factors Driving the SGLT2 Inhibitors Market Growing SGLT2 inhibitors target population Global diabetes prevalence and the rising burden of CKD and heart failure expand the addressable market; demographic trends (aging population, obesity) magnify demand...
PR Newswire
23/09/2025

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

BiogenInc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.The letter did not cite any deficiencies in the clinical data of...
Nasdaq GlobeNewswire
23/09/2025

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial CourtNANTES, France – September 23, 2025, 10:30 p.m. CET – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE) acknowledges the decision rendered on September 23, 2025, by the Nantes Commercial Court rejecting its claims in the proceedings concerning the declaration of concerted action by a group of minority shareholders.In the best interests of the Company, in order to focus on the execution of its...
Nasdaq GlobeNewswire
23/09/2025

Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with Three New…

The 5 mg/250 mL and 10 mg/250 mL concentrations align with the American Society of Health-System Pharmacists (ASHP) Standardize 4 Safety Initiative, supporting efforts to reduce medication errors and enhance patient safety. The 5 mg/250 mL and 10 mg/250 mL concentrations align with the American Society of Health-System Pharmacists (ASHP)Standardize 4 Safety Initiative, supporting efforts to reduce medication errors and enhance patient safety. ADRENALIN ®is the first FDA-approved,...
PR Newswire
23/09/2025

Nyxoah Provides an Update on Expanded Middle East Presence

Nyxoah Provides an Update on Expanded Middle East PresenceNew Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East,...
Nasdaq GlobeNewswire
23/09/2025

LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly

"We congratulate Frank and the Remedium team on this important milestone with Lilly," said Andrew Worden, Founding Partner at Lifespan Vision Ventures. "It is a powerful validation of their platform and is an important step toward developing interventions that extend healthspan. We're excited to support Remedium as they scale their platform and translate it into therapies that can benefit millions of patients." "We congratulate Frank and the Remedium team on this…
PR Newswire
23/09/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from September 15th to September 19th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150300...
Nasdaq GlobeNewswire
23/09/2025

LUMIBIRD : H1 2025 RESULTS SHOW STRONG GROWTH IN BOTH DIVISIONS

Group EBITDA at €20.2 million (+85%), representing 18.9% of revenue Medical Division: EBITDA of €12.1 million, representing 21.8% of revenue (vs. 17.6% in H1 2024) Photonics Division: EBITDA of €8.1 million, representing 15.8% of revenue (vs. 4.3% in H1 2024) The Lumibird Group, European leader in laser technologies, posted significantly improved…
Actusnews Wire
23/09/2025

With 8.2% CAGR Chronic Total Occlusion Market Size Surges US$ 4.22 billion by…

Built for Complexity: CTO Solutions Gaining Momentum Built for Complexity: CTO Solutions Gaining Momentum Chronic Total Occlusion Market to Surge with Demand for Advanced, High-Precision Interventional DevicesValued at US$2.44 billionin 2024. Themarketis projected to reach US$4.22 billionby 2031, registering a strongCAGR of 8.2% (2025–2031). This growth is driven by Increasing Aging Population, growing Prevalence of Cardiovascular Diseases, and emerging healthcare...
PR Newswire
23/09/2025

Kidney Dialysis Equipment Market is projected to reach US$27.04 billion by 2031…

Kidney Dialysis Equipment Market Set to Soar with Demand for Personalized, Patient-Centric Care within the dialysis equipment landscape Kidney Dialysis Equipment Market Set to Soar with Demand for Personalized, Patient-Centric Care within the dialysis equipment landscape Valued at US$17.23 billionin 2024. Themarketis projected to reach US$27.04 billionby 2031, registering a strongCAGR of 6.8% (2025–2031). This growth is driven by rising cases of chronic kidney disease and...
PR Newswire
23/09/2025

With 5% CAGR Paracetamol Market is expected to grow US$15.03 billion by 2031…

Check valuable insights in the Paracetamol Market report. You can easily get a sample PDF of the report -https://www.theinsightpartners.com/sample/TIPRE00038952 Check valuable insights in the Paracetamol Market report. You can easily get a sample PDF of the report -https://www.theinsightpartners.com/sample/TIPRE00038952 Paracetamol Market Set to Soar with Demand for Over-The-Counter (OTC) AnalgesicsValued at US$10.75 billionin 2024. Themarketis projected to reach US$15...
PR Newswire
23/09/2025
Altri  Comunicati